{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:16:00Z","timestamp":1781630160283,"version":"3.54.5"},"reference-count":54,"publisher":"Hamad bin Khalifa University Press (HBKU Press)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>Background: Rituximab is used as second-line therapy in patients with immune thrombocytopenic purpura (ITP) who do not respond to first-line management. The response rate for Rituximab is variable in different populations ranging from 30% to 90%. The adverse effects of rituximab in patients with ITP range from infusion site reactions to the reactivation of hepatitis B virus and progressive multifocal leukoencephalopathy and interpopulation variation.<\/jats:p>\n                  <jats:p>Methods: We conducted a single-center, retrospective study in Qatar's National Center for Cancer Care &amp; Research. The study included patients with chronic refractory ITP who received rituximab as second-line therapy. Descriptive and summary statistics were used to describe the sociodemographic parameters of the study cohort.<\/jats:p>\n                  <jats:p>Results: Of the 41 patients with chronic ITP, 26 were Arabs, 12 were Asians, and 3 were of other ethnicities. Rituximab was associated with an overall response rate of 80.4%. Arabic patients had the highest clinical response (84.6%) among the ethnicities with the lowest adverse effects (11.5%). Asians had a response rate of 66.6%, and adverse effects were seen in 16.7% of the patients.<\/jats:p>\n                  <jats:p>Conclusions: In chronic refractory ITP, rituximab appears to have a better clinical response in the Arabic population with minimal toxicity than in other ethnicities.<\/jats:p>","DOI":"10.5339\/qmj.2022.22","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T13:30:29Z","timestamp":1657373429000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population"],"prefix":"10.5339","volume":"2022","author":[{"given":"Fateen","family":"Ata","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: Fata@hamad.qa;docfateenata@gmail.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohaib","family":"Yousaf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: Fata@hamad.qa;docfateenata@gmail.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathima Z.","family":"Zahir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: Fata@hamad.qa;docfateenata@gmail.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Mohamed Babiker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: Fata@hamad.qa;docfateenata@gmail.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Ali Farooqi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: Fata@hamad.qa;docfateenata@gmail.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mousa","family":"Ahmad Al Hiyari","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: Fata@hamad.qa;docfateenata@gmail.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel Issam","family":"Al Bozom","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: Fata@hamad.qa;docfateenata@gmail.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hatim.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: Fata@hamad.qa;docfateenata@gmail.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulqadir J.","family":"Nashwan","sequence":"additional","affiliation":[{"name":"Department of Nursing for Education & Practice Development, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology\/Hematology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3277","reference":[{"issue":"(2:)","key":"CIT0001","series-title":"Current Opinion in Hematology","first-page":"515-9","article-title":"The epidemiology of immune thrombocytopenic purpura","volume":"14"},{"issue":"(2:)","key":"CIT0002","series-title":"American journal of hematology","first-page":"841-2","article-title":"Immune thrombocytopenic: getting back to basics","volume":"87"},{"issue":"(2)","key":"CIT0003","series-title":"J Clin Med","article-title":"Pathogenesis\u00a0and\u00a0Therapeutic\u00a0Mechanisms\u00a0in Immune\u00a0Thrombocytopenia\u00a0(ITP)","volume":"6"},{"issue":"Suppl 2:","key":"CIT0004","series-title":"Clin Microbiol Infect","first-page":"S71-s82","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24"},{"issue":"(2:)","key":"CIT0005","series-title":"Blood Adv","first-page":"3780-817","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenic","volume":"3"},{"issue":"(2:)","key":"CIT0006","series-title":"Lancet Haematol","first-page":"e75-81","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenic: a systematic review and meta-analysis","volume":"2"},{"issue":"12:","key":"CIT0007","series-title":"J Blood Med","first-page":"653-64","article-title":"Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice"},{"issue":"(2:)","key":"CIT0008","series-title":"Ann Intern Med","first-page":"25-33","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146"},{"issue":"(2:)","key":"CIT0009","series-title":"Int J Hematol","first-page":"654-61","article-title":"Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenic refractory to conventional therapy","volume":"102"},{"issue":"(2:)","key":"CIT0010","series-title":"Ann Hematol","first-page":"239-43","article-title":"Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP)","volume":"88"},{"issue":"(2:)","key":"CIT0011","series-title":"Blood","first-page":"999-1004","article-title":"Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study","volume":"112"},{"issue":"(2:)","key":"CIT0012","series-title":"Blood","first-page":"952-7","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98"},{"key":"CIT0013","article-title":"jamovi (Version 1.2) [Computer Software] 2020"},{"issue":"(2:)","key":"CIT0014","series-title":"Blood","first-page":"3228-36","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenic: results from a prospective registry including 248 patients","volume":"124"},{"issue":"(10 Suppl):","key":"CIT0015","series-title":"J Natl Med Assoc","first-page":"1-26","article-title":"Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment","volume":"94"},{"issue":"(2:)","key":"CIT0016","series-title":"Nature Education","first-page":"212","article-title":"Pharmacogenetics, Personalized Medicine, and Race","volume":"1"},{"issue":"(2:)","key":"CIT0017","series-title":"Blood","first-page":"640-3","article-title":"Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences","volume":"136"},{"issue":"(2:)","key":"CIT0018","series-title":"Journal of Translational Medicine","first-page":"180","article-title":"How personalised medicine will transform healthcare by 2030: the ICPerMed vision","volume":"18"},{"issue":"(2:)","key":"CIT0019","series-title":"Neurotherapeutics","first-page":"1768-84","article-title":"The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis","volume":"17"},{"issue":"(2:)","key":"CIT0020","series-title":"British Journal of Haematology","first-page":"232-9","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125"},{"issue":"(2:)","key":"CIT0021","series-title":"Eur J Haematol","first-page":"95-100","article-title":"Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study","volume":"69"},{"issue":"(2:)","key":"CIT0022","series-title":"Am J Hematol","first-page":"1314-24","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenic: Results at 5?years from the French prospective registry ITP-ritux","volume":"94"},{"issue":"(2:)","key":"CIT0023","series-title":"Jama","first-page":"2004-11","article-title":"II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents","volume":"248"},{"issue":"(2:)","key":"CIT0024","series-title":"Circulation","first-page":"1383-93","article-title":"Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics","volume":"118"},{"issue":"(2:)","key":"CIT0025","series-title":"Expert Opin Drug Metab Toxicol","first-page":"1089-97","article-title":"Influence of ethnicity on response to asthma drugs","volume":"11"},{"issue":"(2:)","key":"CIT0026","series-title":"J Clin Psychiatry","first-page":"9-14","article-title":"Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups","volume":"63"},{"issue":"(2:)","key":"CIT0027","series-title":"Psychiatr Serv","first-page":"1167-79","article-title":"Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial","volume":"62"},{"issue":"(2:)","key":"CIT0001","series-title":"Current Opinion in Hematology","first-page":"515-9","article-title":"The epidemiology of immune thrombocytopenic purpura","volume":"14"},{"issue":"(2:)","key":"CIT0002","series-title":"American journal of hematology","first-page":"841-2","article-title":"Immune thrombocytopenic: getting back to basics","volume":"87"},{"issue":"(2)","key":"CIT0003","series-title":"J Clin Med","article-title":"Pathogenesis\u00a0and\u00a0Therapeutic\u00a0Mechanisms\u00a0in Immune\u00a0Thrombocytopenia\u00a0(ITP)","volume":"6"},{"issue":"Suppl 2:","key":"CIT0004","series-title":"Clin Microbiol Infect","first-page":"S71-s82","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24"},{"issue":"(2:)","key":"CIT0005","series-title":"Blood Adv","first-page":"3780-817","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenic","volume":"3"},{"issue":"(2:)","key":"CIT0006","series-title":"Lancet Haematol","first-page":"e75-81","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenic: a systematic review and meta-analysis","volume":"2"},{"issue":"12:","key":"CIT0007","series-title":"J Blood Med","first-page":"653-64","article-title":"Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice"},{"issue":"(2:)","key":"CIT0008","series-title":"Ann Intern Med","first-page":"25-33","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146"},{"issue":"(2:)","key":"CIT0009","series-title":"Int J Hematol","first-page":"654-61","article-title":"Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenic refractory to conventional therapy","volume":"102"},{"issue":"(2:)","key":"CIT0010","series-title":"Ann Hematol","first-page":"239-43","article-title":"Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP)","volume":"88"},{"issue":"(2:)","key":"CIT0011","series-title":"Blood","first-page":"999-1004","article-title":"Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study","volume":"112"},{"issue":"(2:)","key":"CIT0012","series-title":"Blood","first-page":"952-7","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98"},{"key":"CIT0013","article-title":"jamovi (Version 1.2) [Computer Software] 2020"},{"issue":"(2:)","key":"CIT0014","series-title":"Blood","first-page":"3228-36","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenic: results from a prospective registry including 248 patients","volume":"124"},{"issue":"(10 Suppl):","key":"CIT0015","series-title":"J Natl Med Assoc","first-page":"1-26","article-title":"Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment","volume":"94"},{"issue":"(2:)","key":"CIT0016","series-title":"Nature Education","first-page":"212","article-title":"Pharmacogenetics, Personalized Medicine, and Race","volume":"1"},{"issue":"(2:)","key":"CIT0017","series-title":"Blood","first-page":"640-3","article-title":"Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences","volume":"136"},{"issue":"(2:)","key":"CIT0018","series-title":"Journal of Translational Medicine","first-page":"180","article-title":"How personalised medicine will transform healthcare by 2030: the ICPerMed vision","volume":"18"},{"issue":"(2:)","key":"CIT0019","series-title":"Neurotherapeutics","first-page":"1768-84","article-title":"The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis","volume":"17"},{"issue":"(2:)","key":"CIT0020","series-title":"British Journal of Haematology","first-page":"232-9","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125"},{"issue":"(2:)","key":"CIT0021","series-title":"Eur J Haematol","first-page":"95-100","article-title":"Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study","volume":"69"},{"issue":"(2:)","key":"CIT0022","series-title":"Am J Hematol","first-page":"1314-24","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenic: Results at 5?years from the French prospective registry ITP-ritux","volume":"94"},{"issue":"(2:)","key":"CIT0023","series-title":"Jama","first-page":"2004-11","article-title":"II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents","volume":"248"},{"issue":"(2:)","key":"CIT0024","series-title":"Circulation","first-page":"1383-93","article-title":"Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics","volume":"118"},{"issue":"(2:)","key":"CIT0025","series-title":"Expert Opin Drug Metab Toxicol","first-page":"1089-97","article-title":"Influence of ethnicity on response to asthma drugs","volume":"11"},{"issue":"(2:)","key":"CIT0026","series-title":"J Clin Psychiatry","first-page":"9-14","article-title":"Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups","volume":"63"},{"issue":"(2:)","key":"CIT0027","series-title":"Psychiatr Serv","first-page":"1167-79","article-title":"Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial","volume":"62"}],"container-title":["Qatar Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2022\/3\/article-22.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2022\/3\/article-22.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2022\/3\/article-22.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:10:38Z","timestamp":1777309838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2022\/3\/article-22.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":54,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.5339\/qmj.2022.22","relation":{},"ISSN":["2227-0426"],"issn-type":[{"value":"2227-0426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}